Douglas E. Vaughan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Douglas E. Vaughan has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
Mesut Eren
Feinberg Cardiovascular and Renal Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
13 shared publications- Asish K. Ghosh
Feinberg Cardiovascular and Renal Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
8 shared publications Toshio Miyata
United Centers for Advanced Research and Translational Medicine, Tohoku University, Miyagi, Japan
7 shared publicationsSheila B. Murphy
From Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, IL
5 shared publicationsAmanda E. Boe
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America; Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America
4 shared publicationsAsish K. Ghosh
Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
4 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (12)
Functional, molecular, and digital measurements of biological age
The reality of an aging population demands a deeper understanding of aging as a biological process, rather than as a chronological descriptor. Chronological age poorly captures interindividual heterogeneity in physiological and functional decline, disease susceptibility, and mortality risk. In contrast, biological age encompasses deterioration at the molecular, cellular, tissue, organ, functional, and organismal levels and provides insight into why two individuals with the same chronological age exhibit differences in physiological function, disease susceptibility, and mortality risk. While early models of biological age relied on functional markers or composite scores derived largely from longitudinal cohort studies, more recent models integrate molecular profiling with machine learning to ascertain biological aging trajectories. In parallel, new artificial intelligence tools have been applied to various imaging modalities and other forms of complex data to elucidate latent patterns and estimate biological age. In this state-of-the-art Review, we explore historical and modern approaches to estimating biological age and highlight key conceptual, technical, and translational challenges that remain unresolved. As geroscience-guided interventions are incorporated into clinical evaluations, robust and accurate interpretable measures of biological aging are crucial to ascertain treatment effects in clinical trials.
- 15 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (12)
Open AccessFunctional, molecular, and digital measurements of biological age
The reality of an aging population demands a deeper understanding of aging as a biological process, rather than as a chronological descriptor. Chronological age poorly captures interindividual heterogeneity in physiological and functional decline, disease susceptibility, and mortality risk. In contrast, biological age encompasses deterioration at the molecular, cellular, tissue, organ, functional, and organismal levels and provides insight into why two individuals with the same chronological age exhibit differences in physiological function, disease susceptibility, and mortality risk. While early models of biological age relied on functional markers or composite scores derived largely from longitudinal cohort studies, more recent models integrate molecular profiling with machine learning to ascertain biological aging trajectories. In parallel, new artificial intelligence tools have been applied to various imaging modalities and other forms of complex data to elucidate latent patterns and estimate biological age. In this state-of-the-art Review, we explore historical and modern approaches to estimating biological age and highlight key conceptual, technical, and translational challenges that remain unresolved. As geroscience-guided interventions are incorporated into clinical evaluations, robust and accurate interpretable measures of biological aging are crucial to ascertain treatment effects in clinical trials.
- Open Access
- 15 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (12)
A tribute to Eugene Braunwald (1929–2026)
- 15 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (12)
Open AccessA tribute to Eugene Braunwald (1929–2026)
- Open Access
Targeted Analysis of >1500 Plasma Proteoforms via Individual Ion Mass Spectrometry
Plasma proteomics has long sought to accessibly sense human biology, precisely detect disease states, and advance diagnostics through clinical translation. In recent years, companies with defined panels such as Olink and Somascan have entered the field to complement bottom-up mass spectrometry (BUP). This study leverages a novel mass spectrometry platform to capture targeted proteoform information lost by mainline antibody-, aptamer-, and BUP-driven workflows. The Plasma Proteoform Assay (PPA) uses Individual Ion Mass Spectrometry (I2MS) to resolve mixtures of intact proteins presented by direct injection. Two proteoform panels, PPA 526 and PPA 1514, were defined from human plasma samples obtained from 81 individuals. The panels quantify 526 proteoforms derived from 59 genes and 1,514 proteoforms from 155 genes, respectively. Reproducibility for both panels showed coefficients of variation below 20% for most proteoforms (59-80%). PPA was benchmarked in studies including subjects with hepatic cirrhosis (N=30) and resilient agers carrying a SERPINE1 (PAI 1) mutation (N=27). PPA signatures distinguished SERPINE1 mutation carriers from affected individuals and provided sufficient resolution to discriminate among cirrhosis disease stages. In summary, we present PPA 526 and PPA 1514, the first scalable plasma proteoform panels capable of tracking hundreds to thousands of targets in a few minutes per sample.
Open AccessTargeted Analysis of >1500 Plasma Proteoforms via Individual Ion Mass Spectrometry
Plasma proteomics has long sought to accessibly sense human biology, precisely detect disease states, and advance diagnostics through clinical translation. In recent years, companies with defined panels such as Olink and Somascan have entered the field to complement bottom-up mass spectrometry (BUP). This study leverages a novel mass spectrometry platform to capture targeted proteoform information lost by mainline antibody-, aptamer-, and BUP-driven workflows. The Plasma Proteoform Assay (PPA) uses Individual Ion Mass Spectrometry (I2MS) to resolve mixtures of intact proteins presented by direct injection. Two proteoform panels, PPA 526 and PPA 1514, were defined from human plasma samples obtained from 81 individuals. The panels quantify 526 proteoforms derived from 59 genes and 1,514 proteoforms from 155 genes, respectively. Reproducibility for both panels showed coefficients of variation below 20% for most proteoforms (59-80%). PPA was benchmarked in studies including subjects with hepatic cirrhosis (N=30) and resilient agers carrying a SERPINE1 (PAI 1) mutation (N=27). PPA signatures distinguished SERPINE1 mutation carriers from affected individuals and provided sufficient resolution to discriminate among cirrhosis disease stages. In summary, we present PPA 526 and PPA 1514, the first scalable plasma proteoform panels capable of tracking hundreds to thousands of targets in a few minutes per sample.
- Open Access
- 30 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (23)
Plasminogen activator inhibitor 1 promotes aortic aging–like pathophysiology in humans and mice
Plasminogen activator inhibitor 1 (PAI-1), encoded by SERPINE1 , contributes to age-related cardiovascular disease (CVD) and other aging-related pathologies. Humans with a heterozygous loss-of-function SERPINE1 variant exhibit protection against aging and cardiometabolic dysfunction. We engineered a mouse model mimicking the human mutation ( Serpine1 TA700/+ ) and compared cardiovascular responses with WT littermates. Serpine1 TA700/+ mice lived 17% longer than did littermate control mice. Under l-N G -nitro-arginine methyl ester–induced (l-NAME–induced) vascular stress, Serpine1 TA700/+ mice exhibited diminished pulse wave velocity (PWV), lower systolic blood pressure (SBP), and preserved left ventricular diastolic function compared with controls. Conversely, PAI-1–overexpressing mice had measurements indicating accelerated cardiovascular aging. Single-cell transcriptomics of Serpine1 TA700/+ aortas revealed a vascular-protective mechanism with downregulation of the extracellular matrix regulators Ccn1 and Itgb1 . Serpine1 TA700/+ aortas were also enriched in a cluster of smooth muscle cells that exhibited plasticity. Finally, PAI-1 pharmacological inhibition normalized SBP and reversed l-NAME–induced PWV elevation. These findings demonstrate that PAI-1 reduction protects against cardiovascular aging-related phenotypes, while PAI-1 excess promotes vascular pathological changes. Taken together, PAI-1 inhibition represents a promising strategy to mitigate age-related CVD.
- 30 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (23)
Open AccessPlasminogen activator inhibitor 1 promotes aortic aging–like pathophysiology in humans and mice
Plasminogen activator inhibitor 1 (PAI-1), encoded by SERPINE1 , contributes to age-related cardiovascular disease (CVD) and other aging-related pathologies. Humans with a heterozygous loss-of-function SERPINE1 variant exhibit protection against aging and cardiometabolic dysfunction. We engineered a mouse model mimicking the human mutation ( Serpine1 TA700/+ ) and compared cardiovascular responses with WT littermates. Serpine1 TA700/+ mice lived 17% longer than did littermate control mice. Under l-N G -nitro-arginine methyl ester–induced (l-NAME–induced) vascular stress, Serpine1 TA700/+ mice exhibited diminished pulse wave velocity (PWV), lower systolic blood pressure (SBP), and preserved left ventricular diastolic function compared with controls. Conversely, PAI-1–overexpressing mice had measurements indicating accelerated cardiovascular aging. Single-cell transcriptomics of Serpine1 TA700/+ aortas revealed a vascular-protective mechanism with downregulation of the extracellular matrix regulators Ccn1 and Itgb1 . Serpine1 TA700/+ aortas were also enriched in a cluster of smooth muscle cells that exhibited plasticity. Finally, PAI-1 pharmacological inhibition normalized SBP and reversed l-NAME–induced PWV elevation. These findings demonstrate that PAI-1 reduction protects against cardiovascular aging-related phenotypes, while PAI-1 excess promotes vascular pathological changes. Taken together, PAI-1 inhibition represents a promising strategy to mitigate age-related CVD.
- Top Cited PapersOpen Access
- 22 April 2025
- Published by OAE Publishing Inc. in The Journal of Cardiovascular Aging
- Vol. 5 (2)
Role of plasminogen activator inhibitor-1 (PAI-1) in age-related cardiovascular pathophysiology
Cardiovascular aging underpins the development of age-related diseases, including heart failure and vascular dysfunction, and is driven by molecular and cellular mechanisms described in the hallmarks of aging. Plasminogen activator inhibitor-1 (PAI-1), a key regulator of fibrinolysis, also mediates processes like vascular stiffness, cellular senescence, and immune evasion. This review highlights PAI-1’s role in cardiovascular aging with a special emphasis on senescence, a key hallmark of aging. It further explores PAI-1’s therapeutic potential, with a focus on its contribution to ECM remodeling, senescence signaling, and immune checkpoint regulation. Targeting PAI-1 could provide a promising strategy to mitigate age-related cardiovascular disease.
- 22 April 2025
- Published by OAE Publishing Inc. in The Journal of Cardiovascular Aging
- Vol. 5 (2)
Top Cited PapersOpen AccessRole of plasminogen activator inhibitor-1 (PAI-1) in age-related cardiovascular pathophysiology
Cardiovascular aging underpins the development of age-related diseases, including heart failure and vascular dysfunction, and is driven by molecular and cellular mechanisms described in the hallmarks of aging. Plasminogen activator inhibitor-1 (PAI-1), a key regulator of fibrinolysis, also mediates processes like vascular stiffness, cellular senescence, and immune evasion. This review highlights PAI-1’s role in cardiovascular aging with a special emphasis on senescence, a key hallmark of aging. It further explores PAI-1’s therapeutic potential, with a focus on its contribution to ECM remodeling, senescence signaling, and immune checkpoint regulation. Targeting PAI-1 could provide a promising strategy to mitigate age-related cardiovascular disease.
- Open Access
- 15 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Mouse model hints at pharmacogenomic strategies for stroke treatment in patients possessing a risk variant
- 15 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Open AccessMouse model hints at pharmacogenomic strategies for stroke treatment in patients possessing a risk variant
- Open Access
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (26) , eadf8140
Inequalities in urban greenness and epigenetic aging: Different associations by race and neighborhood socioeconomic status
Slower epigenetic aging is associated with exposure to green space (greenness); however, the longitudinal relationship has not been well studied, particularly in minority groups. We investigated the association between 20-year exposure to greenness [Normalized Difference Vegetation Index (NDVI)] and epigenetic aging in a large, biracial (Black/white), U.S. urban cohort. Using generalized estimating equations adjusted for individual and neighborhood socioeconomic characteristics, greater greenness was associated with slower epigenetic aging. Black participants had less surrounding greenness and an attenuated association between greenness and epigenetic aging [β NDVI5km : −0.80, 95% confidence interval (CI): −4.75, 3.13 versus β NDVI5km : −3.03, 95% CI: −5.63, −0.43 in white participants]. Participants in disadvantaged neighborhoods showed a stronger association between greenness and epigenetic aging (β NDVI5km : −3.36, 95% CI: −6.65, −0.08 versus β NDVI5km : −1.57, 95% CI: −4.12, 0.96 in less disadvantaged). In conclusion, we found a relationship between greenness and slower epigenetic aging, and different associations by social determinants of health such as race and neighborhood socioeconomic status.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (26) , eadf8140
Open AccessInequalities in urban greenness and epigenetic aging: Different associations by race and neighborhood socioeconomic status
Slower epigenetic aging is associated with exposure to green space (greenness); however, the longitudinal relationship has not been well studied, particularly in minority groups. We investigated the association between 20-year exposure to greenness [Normalized Difference Vegetation Index (NDVI)] and epigenetic aging in a large, biracial (Black/white), U.S. urban cohort. Using generalized estimating equations adjusted for individual and neighborhood socioeconomic characteristics, greater greenness was associated with slower epigenetic aging. Black participants had less surrounding greenness and an attenuated association between greenness and epigenetic aging [β NDVI5km : −0.80, 95% confidence interval (CI): −4.75, 3.13 versus β NDVI5km : −3.03, 95% CI: −5.63, −0.43 in white participants]. Participants in disadvantaged neighborhoods showed a stronger association between greenness and epigenetic aging (β NDVI5km : −3.36, 95% CI: −6.65, −0.08 versus β NDVI5km : −1.57, 95% CI: −4.12, 0.96 in less disadvantaged). In conclusion, we found a relationship between greenness and slower epigenetic aging, and different associations by social determinants of health such as race and neighborhood socioeconomic status.
- Open Access
- 27 December 2022
- Published by Elsevier in Cellular Signalling
- Vol. 104, 110555
Cardiomyocyte PAI-1 influences the cardiac transcriptome and limits the extent of cardiac fibrosis in response to left ventricular pressure overload
- 27 December 2022
- Published by Elsevier in Cellular Signalling
- Vol. 104, 110555
Open AccessCardiomyocyte PAI-1 influences the cardiac transcriptome and limits the extent of cardiac fibrosis in response to left ventricular pressure overload
- Open Access
- 1 July 2021
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 6 (7) , 841-846
Identification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in SERPINE1
Quiz Ref ID Plasminogen activator inhibitor-1 (PAI-1) plays a key role in regulating fibrinolysis through inhibition of urokinase-type plasminogen activator and tissue-type plasminogen activator.1 Beyond this well-established role, PAI-1 regulates cell migration, senescence, and extracellular matrix deposition, each of which contribute to fibrosis.2 Quiz Ref ID In experimental models, increased PAI-1 levels correlate with fibrosis in vitro and in vivo.1 Counterintuitively, the absence of PAI-12,3 has been reported to cause spontaneous cardiac fibrosis in murine models, suggesting the need of an optimal range of PAI-1 for cardiac homeostasis.
- 1 July 2021
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 6 (7) , 841-846
Open AccessIdentification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in SERPINE1
Quiz Ref ID Plasminogen activator inhibitor-1 (PAI-1) plays a key role in regulating fibrinolysis through inhibition of urokinase-type plasminogen activator and tissue-type plasminogen activator.1 Beyond this well-established role, PAI-1 regulates cell migration, senescence, and extracellular matrix deposition, each of which contribute to fibrosis.2 Quiz Ref ID In experimental models, increased PAI-1 levels correlate with fibrosis in vitro and in vivo.1 Counterintuitively, the absence of PAI-12,3 has been reported to cause spontaneous cardiac fibrosis in murine models, suggesting the need of an optimal range of PAI-1 for cardiac homeostasis.
- Open Access
Pharmacological inhibition of PAI-1 alleviates cardiopulmonary pathologies induced by exposure to air pollutants PM 2.5
OBJECTIVE: Exposure to air pollutants leads to the development of pulmonary and cardiovascular diseases, and thus air pollution is one of the major global threats to human health. Air pollutant particulate matter 2.5 (PM 2.5 )-induced cellular dysfunction impairs tissue homeostasis and causes vascular and cardiopulmonary damage. To test a hypothesis that elevated plasminogen activator inhibitor-1 (PAI-1) levels play a pivotal role in air pollutant-induced cardiopulmonary pathologies, we examined the efficacy of a drug-like novel inhibitor of PAI-1, TM5614, in treating PM 2.5 -induced vascular and cardiopulmonary pathologies. APPROACH AND RESULTS: Results from biochemical, histological, and immunohistochemical studies revealed that PM 2.5 increases the circulating levels of PAI-1 and thrombin and that TM5614 treatment completely abrogates these effects in plasma. PM 2.5 significantly augments levels of pro-inflammatory cytokine IL-6 in bronchoalveolar lavage fluid, and this also can be reversed by TM5614, indicating its efficacy in amelioration of PM 2.5 -induced increases in inflammatory and pro-thrombotic factors. TM5614 reduces PM 2.5 -induced increased levels of inflammatory markers Mac3 and pSTAT3, adhesion molecule VCAM1, and apoptotic marker cleaved caspase 3. Longer exposure to PM 2.5 induces pulmonary and cardiac thrombosis, but TM5614 significantly ameliorates PM 2.5 -induced vascular thrombosis. TM5614 also reduces PM 2.5 -induced increased blood pressure and heart weight. In vitro cell culture studies revealed that PM 2.5 induces the levels of PAI-1, type I collagen, fibronectin, and SREBP-1/2, a transcription factor that mediates profibrogenic signaling, in cardiac fibroblasts. TM5614 abrogated that stimulation, indicating that it may block PM 2.5 -induced PAI-1 and profibrogenic signaling through suppression of SREBP-1. Furthermore, TM5614 blocked PM 2.5 -mediated suppression of Nrf2, a major antioxidant regulator in cardiac fibroblasts. CONCLUSIONS: Pharmacological inhibition of PAI-1 with TM5614 is a promising therapeutic approach to control air pollutant PM 2.5 -induced cardiopulmonary and vascular pathologies. Abstract Figure:
Open AccessPharmacological inhibition of PAI-1 alleviates cardiopulmonary pathologies induced by exposure to air pollutants PM 2.5
OBJECTIVE: Exposure to air pollutants leads to the development of pulmonary and cardiovascular diseases, and thus air pollution is one of the major global threats to human health. Air pollutant particulate matter 2.5 (PM 2.5 )-induced cellular dysfunction impairs tissue homeostasis and causes vascular and cardiopulmonary damage. To test a hypothesis that elevated plasminogen activator inhibitor-1 (PAI-1) levels play a pivotal role in air pollutant-induced cardiopulmonary pathologies, we examined the efficacy of a drug-like novel inhibitor of PAI-1, TM5614, in treating PM 2.5 -induced vascular and cardiopulmonary pathologies. APPROACH AND RESULTS: Results from biochemical, histological, and immunohistochemical studies revealed that PM 2.5 increases the circulating levels of PAI-1 and thrombin and that TM5614 treatment completely abrogates these effects in plasma. PM 2.5 significantly augments levels of pro-inflammatory cytokine IL-6 in bronchoalveolar lavage fluid, and this also can be reversed by TM5614, indicating its efficacy in amelioration of PM 2.5 -induced increases in inflammatory and pro-thrombotic factors. TM5614 reduces PM 2.5 -induced increased levels of inflammatory markers Mac3 and pSTAT3, adhesion molecule VCAM1, and apoptotic marker cleaved caspase 3. Longer exposure to PM 2.5 induces pulmonary and cardiac thrombosis, but TM5614 significantly ameliorates PM 2.5 -induced vascular thrombosis. TM5614 also reduces PM 2.5 -induced increased blood pressure and heart weight. In vitro cell culture studies revealed that PM 2.5 induces the levels of PAI-1, type I collagen, fibronectin, and SREBP-1/2, a transcription factor that mediates profibrogenic signaling, in cardiac fibroblasts. TM5614 abrogated that stimulation, indicating that it may block PM 2.5 -induced PAI-1 and profibrogenic signaling through suppression of SREBP-1. Furthermore, TM5614 blocked PM 2.5 -mediated suppression of Nrf2, a major antioxidant regulator in cardiac fibroblasts. CONCLUSIONS: Pharmacological inhibition of PAI-1 with TM5614 is a promising therapeutic approach to control air pollutant PM 2.5 -induced cardiopulmonary and vascular pathologies. Abstract Figure: